Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Non-Customized |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Sorafenib (CAS 284461-73-0) is one anti-cancer drug. Sorafenib (CAS 284461-73-0) can be used in the treatment of primary kidney cancer, and hepatocellular carcinoma. Sorafenib (CAS 284461-73-0) has been formulated into finished dosage forms and marketed under the brand name Nexavar by Bayer and Onyx Pharmaceuticals.
Sorafenib (CAS 284461-73-0) is one API approved by EU and other authorities for the treatment of anti-cancer.
Specification of Sorafenib:
Test Items |
Specification |
Results |
Description |
White to off white crystalline powder |
Comply |
Melting point |
166-170°C |
167.3-168.1°C |
Identification |
Positive reaction |
Positive reaction |
Related substances |
≤1.0% |
0.16% |
Loss on drying |
≤0.5% |
0.06% |
Residue on ignition |
≤0.1% |
0.02% |
Chloride |
≤0.014% |
<0.014 |
Heavy Metals |
≤20ppm |
<20ppm |
Clarity of solution |
Conform to standard |
Complies |
Microbial Limit |
≤20ppm |
<20ppm |
Assay |
≥99.0% |
99.12% |
1. Sorafenib is a novel multi-targeted antitumor drug that acts on both tumor cells and tumor blood vessels. It has dual anti-tumor effects: it can directly inhibit tumor cell proliferation by blocking the cell signaling pathway mediated by RAF/MEK/ERK, and indirectly inhibit tumor cell growth by blocking the formation of tumor neovascularization through inhibiting VE GF and platelet-derived growth fact or (PD GF) receptors.
2. Sorafenib is a novel multi-targeted oral drug for the treatment of tumors
3. Multiple kinase inhibitor targeting both RAF kinase and receptor tyrosine kinases that promote angiogensis. Antineoplastic.
Qingdao Sigma Chemical Co.,Ltd is a global chemical industry manufacturers and suppliers of pharmaceuticals and intermediates, food and feed additives, herbal extracts, agrochemicals and fine chemicals etc.